+

WO2003046553A1 - Diagnostic de la bronchopneumopathie chronique obstructive - Google Patents

Diagnostic de la bronchopneumopathie chronique obstructive Download PDF

Info

Publication number
WO2003046553A1
WO2003046553A1 PCT/JP2002/012421 JP0212421W WO03046553A1 WO 2003046553 A1 WO2003046553 A1 WO 2003046553A1 JP 0212421 W JP0212421 W JP 0212421W WO 03046553 A1 WO03046553 A1 WO 03046553A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid sequence
same
diagnostics
pulmonary disease
Prior art date
Application number
PCT/JP2002/012421
Other languages
English (en)
Japanese (ja)
Inventor
Atsushi Nakanishi
Shigeru Morita
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Priority to AU2002354072A priority Critical patent/AU2002354072A1/en
Publication of WO2003046553A1 publication Critical patent/WO2003046553A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne le diagnostic de l'asthme ou de la bronchopneumopathie chronique obstructive. De manière plus spécifique, le diagnostic de maladies respiratoires se caractérise en ce qu'il fait intervenir : (1) un anticorps dirigé contre une protéine comprenant une séquence d'acides aminés identique ou sensiblement identique à la séquence d'acides aminés représentée par SEQ ID NO:1 ; (2) un anticorps dirigé contre une protéine comprenant une séquence d'acides aminés identique ou sensiblement identique à la séquence d'acides aminés représentée par SEQ ID NO:2 ; et (3) un anticorps dirigé contre une protéine comprenant une séquence d'acides aminés identique ou sensiblement identique à la séquence d'acides aminés représentée par SEQ ID NO:3.
PCT/JP2002/012421 2001-11-29 2002-11-28 Diagnostic de la bronchopneumopathie chronique obstructive WO2003046553A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002354072A AU2002354072A1 (en) 2001-11-29 2002-11-28 Diagnostics for chronic obstructive pulmonary disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-364715 2001-11-29
JP2001364715 2001-11-29

Publications (1)

Publication Number Publication Date
WO2003046553A1 true WO2003046553A1 (fr) 2003-06-05

Family

ID=19174855

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/012421 WO2003046553A1 (fr) 2001-11-29 2002-11-28 Diagnostic de la bronchopneumopathie chronique obstructive

Country Status (2)

Country Link
AU (1) AU2002354072A1 (fr)
WO (1) WO2003046553A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044620A1 (fr) * 1998-03-03 1999-09-10 Magainin Pharmaceuticals, Inc. Facteurs associes a l'asthme servant de cibles pour le traitement d'allergies atopiques dont l'asthme et des troubles associes
WO2001038530A1 (fr) * 1999-11-24 2001-05-31 Takeda Chemical Industries, Ltd. Utilisation d'un gene associe a une maladie
WO2002014366A2 (fr) * 2000-08-16 2002-02-21 Universiteit Utrecht Genes impliques dans la reponse immunitaire observee dans l'asthme

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044620A1 (fr) * 1998-03-03 1999-09-10 Magainin Pharmaceuticals, Inc. Facteurs associes a l'asthme servant de cibles pour le traitement d'allergies atopiques dont l'asthme et des troubles associes
WO2001038530A1 (fr) * 1999-11-24 2001-05-31 Takeda Chemical Industries, Ltd. Utilisation d'un gene associe a une maladie
WO2002014366A2 (fr) * 2000-08-16 2002-02-21 Universiteit Utrecht Genes impliques dans la reponse immunitaire observee dans l'asthme

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AGNEL M. ET AL., FEBS LETTERS, vol. 455, no. 3, 1999, pages 295 - 301, XP002945250 *

Also Published As

Publication number Publication date
AU2002354072A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
IL210454A (en) Antibody against a new ligand of cytokine 17zcytor
WO2002068455A3 (fr) Augmentation du taux de recuperation de proteines actives
WO2003070760A3 (fr) Anticorps anti-a$g(b) et leur utilisation
WO2001079444A3 (fr) Proteines hybrides d'albumine
WO2006050166A3 (fr) Methodes de prevention et de traitement des infections a rsv et des etats pathologiques associes
WO2006107824A3 (fr) Controle de la conversion d'acide n-(phosphonomethyl) iminodiacetique lors de la fabrication du glyphosate
WO2006005707A3 (fr) Methode de prevention et de traitement de la maladie d'alzheimer
AU2002366203A1 (en) Medicament dispensing system
WO2003020932A1 (fr) Nouvelles proteines de secretion et adn associe
WO2005051998A3 (fr) Anticorps
MXPA04000597A (es) Peptidos novedosos de la proteina g del virus sincicial respiratorio (rsv), y su uso en una vacuna.
WO2003048207A3 (fr) Anticorps dirige contre le dota
AU2001252192A1 (en) Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (copd)
WO2004082629A3 (fr) Nouvelles cyclosporines
WO2002058725A3 (fr) Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
WO2007058267A8 (fr) Proteine innovante et gene codant pour la proteine
WO2003046553A1 (fr) Diagnostic de la bronchopneumopathie chronique obstructive
AU1309601A (en) Novel protein and dna thereof
WO2003020759A3 (fr) Proteine de liaison de caspase 8, ses procedes de preparation et son utilisation
EP1386961A3 (fr) Réductase modifiée, son gène et utilisation associée
WO2002074034A3 (fr) Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'antagonistes de l'endotheline
AU2003202489A1 (en) Screening method
WO2001002429A3 (fr) Angiopoietine 6 et ses utilisations
WO2003021263A1 (fr) Utilisation d'une proteine de recepteur couple a une proteine g
WO2001060858A3 (fr) Procede de preparation de proteine cationique eosinophile de muqueuse (ecp), ecp de muqueuse, et ses utilisations comme marqueur des phlogoses allergiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载